Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2017
Pfizer objects to NICE methods in leukaemia drug rejection
21 August 2017 - NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give ...
Posted by Michael Wonder on 20 Aug 2017
NICE no takes gloss off Besponsa’s FDA nod
18 August 2017 - Hours after Pfizer announced the news of regulatory approval for its drug Besponsa (inotuzumab ozogamicin) in ...
Posted by Michael Wonder on 14 Aug 2017
NICE turns down kidney cancer drugs
14 August 2017 - It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will ...
Posted by Michael Wonder on 10 Aug 2017
Patients getting faster access to cancer drugs as NICE approves three quarters of the Cancer Drugs Fund
10 August 2017 - Liver cancer drug, sorafenib has been approved for routine NHS use, marking three quarters of the way ...
Posted by Michael Wonder on 09 Aug 2017
Comprehensive assessment of complex technologies: integrating various aspects in health technology assessment
7 August 2017 - Despite recent development of health technology assessment (HTA) methods, there are still methodological gaps for the assessment ...
Posted by Michael Wonder on 09 Aug 2017
NICE supports the use of another treatment option for patients with renal cell carcinoma on the NHS
9 August 2017 - NICE has completed its appraisal of cabozantinib maleate for patients with previously treated advanced renal cell ...
Posted by Michael Wonder on 09 Aug 2017
NICE publishes final guidance for baricitinib
9 August 2017 - NICE has published final guidance on the use of baricitinib for the treatment of patients with ...
Posted by Michael Wonder on 09 Aug 2017
NICE recommends Erbitux
8 August 2017 - NICE recommends Erbitux in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic head and ...
Posted by Michael Wonder on 09 Aug 2017
Thousands more people could be offered drugs to prevent bone fractures because of osteoporosis
9 August 2017 - NICE has published new guidance on the use of drugs called bisphosphonates for preventing bone fractures in ...
Posted by Michael Wonder on 07 Aug 2017
PrEP: HIV 'game-changer' to reach NHS in England from September
3 August 2017 - The NHS in England has announced it will finally give people a drug to dramatically reduce ...
Posted by Michael Wonder on 06 Aug 2017
NICE issues draft guidance on Almirall’s Skilarence for psoriasis
4 August 2017 - NICE, the cost-effectiveness watchdog for England, has issued draft guidance recommending Skilarence (dimethyl fumarate). ...
Posted by Michael Wonder on 04 Aug 2017
How much should we spend on health care?
3 August 2017 - What’s the right amount of spending on health care? And how does the UK’s spending compare ...
Posted by Michael Wonder on 04 Aug 2017
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
4 August 2017 - Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as ...
Posted by Michael Wonder on 04 Aug 2017
Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE
4 August 2017 - NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and ...
Posted by Michael Wonder on 03 Aug 2017
UK finds Roche bladder cancer drug too costly for routine use
3 August 2017 - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to ...